Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.

ABSTRACT:

Background

Minimal residual disease (MRD) is a standard measurement for response assessment in multiple myeloma (MM). Despite new treatments, high-risk MM patients continue to have poor prognosis. We evaluated the effect of MRD negativity in high-risk versus standard-risk patients.

Patients and methods

We retrospectively evaluated all consecutive MM patients who underwent routine MRD testing by 1-tube 8-color advanced flow cytometry with 2,000,000 events and sensitivity level 10^-5 at our center from 2015 to 2018 after initial therapy. Kaplan-Meier and log-rank test were used to assess survival estimates and differences between study groups.

Results

One hundred thirty-six patients with MRD testing after initial therapy or autologous stem-cell transplantation

SUBMITTER: Kunacheewa C 

PROVIDER: S-EPMC7190410 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature